fda tirzepatide weight loss clinical trial results is FDA-approved for management, with trials showing average weight GLP-1 Drugs for Weight Loss:

The drug manufacturer recommends leaving at least 72 hours between injections

In the SURMOUT-1 trial 2,539 patients underwent randomization to tirzepatide or placebo and were followed for 72 weeks demonstrating up to 20.9% weight reduction with maintenance dosing versus 3.1% in the placebo group for a net 17.8% weight reduction [35]

The biggest cons of the drug for her are: Mild constipation The cost and her reliance on health insurance Semaglutide is currently covered by the insurance Steward's husband has through his work, and she knows her access is in the hands of insurance providers

The Medicines and Healthcare products Regulatory Agency (MHRA) and eMC list vomiting as a common adverse reaction to semaglutide